Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group

Holly L. Geyer, Heidi Kosiorek, Amylou Dueck, Robyn Scherber, Stefanie Slot, Sonja Zweegman, Peter A W te Boekhorst, Zhenya Senyak, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Döhner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise BoyerGabriel Etienne, Jean Christophe Ianotto, Dana Ranta, Lydia Roy, Jean Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Chiara Paoli, Francesco Passamonti, Bjorn Andreasson, Maria L. Ferrari, Alessandro Rambaldi, Jan Samuelsson, Keith Cannon, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Jean Jacques Kiladjian, Peihong Zhang, Robert Peter Gale, Ruben A. Mesa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life. The role gender plays in the symptomatology of myeloproliferative neoplasms remains underinvestigated. In this study we evaluated how gender relates to patients’ characteristics, disease complications and overall symptom expression. A total of 2,006 patients (polycythemia vera=711, essential thrombocythemia= 830, myelofibrosis=460, unknown=5) were prospectively evaluated, with patients completing the Myeloproliferative Neoplasm-Symptom Assessment Form and Brief Fatigue Inventory Patient Reported Outcome tools. Information on the individual patients’ characteristics, disease complications and laboratory data was collected. Consistent with known literature, most female patients were more likely to have essential thrombocythemia (48.6% versus 33.0%; P<0.001) and most male patients were more likely to have polycythemia vera (41.8% versus 30.3%; P<0.001). The rate of thrombocytopenia was higher among males than females (13.9% versus 8.2%; P<0.001) and males also had greater redblood cell transfusion requirements (7.3% versus 4.9%; P=0.02) with shorter mean disease duration (6.4 versus 7.2 years, P=0.03). Despite there being no statistical differences in risk scores, receipt of most therapies or prior complications (hemorrhage, thrombosis), females had more severe and more frequent symptoms for most individual symptoms, along with overall total symptom score (22.8 versus 20.3; P<0.001). Females had particularly high scores for abdominal-related symptoms (abdominal pain/discomfort) and microvascular symptoms (headache, fatigue, insomnia, concentration difficulties, dizziness; all P<0.01). Despite complaining of more severe symptom burden, females had similar quality of life scores to those of males. The results of this study suggest that gender contributes to the heterogeneity of myeloproliferative neoplasms by influencing phenotypic profiles and symptom expression.

Original languageEnglish (US)
Pages (from-to)85-93
Number of pages9
JournalHaematologica
Volume102
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Neoplasms
Primary Myelofibrosis
Fatigue
Quality of Life
Symptom Assessment
Sleep Initiation and Maintenance Disorders
Dizziness
Thrombocytopenia
Abdominal Pain
Headache
Thrombosis
Hemorrhage
Equipment and Supplies
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms : An analysis by the MPN QOL international working group. / Geyer, Holly L.; Kosiorek, Heidi; Dueck, Amylou; Scherber, Robyn; Slot, Stefanie; Zweegman, Sonja; te Boekhorst, Peter A W; Senyak, Zhenya; Schouten, Harry C.; Sackmann, Federico; Fuentes, Ana Kerguelen; Hernández-Maraver, Dolores; Pahl, Heike L.; Griesshammer, Martin; Stegelmann, Frank; Döhner, Konstanze; Lehmann, Thomas; Bonatz, Karin; Reiter, Andreas; Boyer, Francoise; Etienne, Gabriel; Ianotto, Jean Christophe; Ranta, Dana; Roy, Lydia; Cahn, Jean Yves; Harrison, Claire N.; Radia, Deepti; Muxi, Pablo; Maldonado, Norman; Besses, Carlos; Cervantes, Francisco; Johansson, Peter L.; Barbui, Tiziano; Barosi, Giovanni; Vannucchi, Alessandro M.; Paoli, Chiara; Passamonti, Francesco; Andreasson, Bjorn; Ferrari, Maria L.; Rambaldi, Alessandro; Samuelsson, Jan; Cannon, Keith; Birgegard, Gunnar; Xiao, Zhijian; Xu, Zefeng; Zhang, Yue; Sun, Xiujuan; Xu, Junqing; Kiladjian, Jean Jacques; Zhang, Peihong; Gale, Robert Peter; Mesa, Ruben A.

In: Haematologica, Vol. 102, No. 1, 2017, p. 85-93.

Research output: Contribution to journalArticle

Geyer, HL, Kosiorek, H, Dueck, A, Scherber, R, Slot, S, Zweegman, S, te Boekhorst, PAW, Senyak, Z, Schouten, HC, Sackmann, F, Fuentes, AK, Hernández-Maraver, D, Pahl, HL, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, JC, Ranta, D, Roy, L, Cahn, JY, Harrison, CN, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, PL, Barbui, T, Barosi, G, Vannucchi, AM, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, ML, Rambaldi, A, Samuelsson, J, Cannon, K, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, JJ, Zhang, P, Gale, RP & Mesa, RA 2017, 'Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group', Haematologica, vol. 102, no. 1, pp. 85-93. https://doi.org/10.3324/haematol.2016.149559
Geyer, Holly L. ; Kosiorek, Heidi ; Dueck, Amylou ; Scherber, Robyn ; Slot, Stefanie ; Zweegman, Sonja ; te Boekhorst, Peter A W ; Senyak, Zhenya ; Schouten, Harry C. ; Sackmann, Federico ; Fuentes, Ana Kerguelen ; Hernández-Maraver, Dolores ; Pahl, Heike L. ; Griesshammer, Martin ; Stegelmann, Frank ; Döhner, Konstanze ; Lehmann, Thomas ; Bonatz, Karin ; Reiter, Andreas ; Boyer, Francoise ; Etienne, Gabriel ; Ianotto, Jean Christophe ; Ranta, Dana ; Roy, Lydia ; Cahn, Jean Yves ; Harrison, Claire N. ; Radia, Deepti ; Muxi, Pablo ; Maldonado, Norman ; Besses, Carlos ; Cervantes, Francisco ; Johansson, Peter L. ; Barbui, Tiziano ; Barosi, Giovanni ; Vannucchi, Alessandro M. ; Paoli, Chiara ; Passamonti, Francesco ; Andreasson, Bjorn ; Ferrari, Maria L. ; Rambaldi, Alessandro ; Samuelsson, Jan ; Cannon, Keith ; Birgegard, Gunnar ; Xiao, Zhijian ; Xu, Zefeng ; Zhang, Yue ; Sun, Xiujuan ; Xu, Junqing ; Kiladjian, Jean Jacques ; Zhang, Peihong ; Gale, Robert Peter ; Mesa, Ruben A. / Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms : An analysis by the MPN QOL international working group. In: Haematologica. 2017 ; Vol. 102, No. 1. pp. 85-93.
@article{962cca65fa8d48e39d00ee003321ca58,
title = "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group",
abstract = "The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life. The role gender plays in the symptomatology of myeloproliferative neoplasms remains underinvestigated. In this study we evaluated how gender relates to patients’ characteristics, disease complications and overall symptom expression. A total of 2,006 patients (polycythemia vera=711, essential thrombocythemia= 830, myelofibrosis=460, unknown=5) were prospectively evaluated, with patients completing the Myeloproliferative Neoplasm-Symptom Assessment Form and Brief Fatigue Inventory Patient Reported Outcome tools. Information on the individual patients’ characteristics, disease complications and laboratory data was collected. Consistent with known literature, most female patients were more likely to have essential thrombocythemia (48.6{\%} versus 33.0{\%}; P<0.001) and most male patients were more likely to have polycythemia vera (41.8{\%} versus 30.3{\%}; P<0.001). The rate of thrombocytopenia was higher among males than females (13.9{\%} versus 8.2{\%}; P<0.001) and males also had greater redblood cell transfusion requirements (7.3{\%} versus 4.9{\%}; P=0.02) with shorter mean disease duration (6.4 versus 7.2 years, P=0.03). Despite there being no statistical differences in risk scores, receipt of most therapies or prior complications (hemorrhage, thrombosis), females had more severe and more frequent symptoms for most individual symptoms, along with overall total symptom score (22.8 versus 20.3; P<0.001). Females had particularly high scores for abdominal-related symptoms (abdominal pain/discomfort) and microvascular symptoms (headache, fatigue, insomnia, concentration difficulties, dizziness; all P<0.01). Despite complaining of more severe symptom burden, females had similar quality of life scores to those of males. The results of this study suggest that gender contributes to the heterogeneity of myeloproliferative neoplasms by influencing phenotypic profiles and symptom expression.",
author = "Geyer, {Holly L.} and Heidi Kosiorek and Amylou Dueck and Robyn Scherber and Stefanie Slot and Sonja Zweegman and {te Boekhorst}, {Peter A W} and Zhenya Senyak and Schouten, {Harry C.} and Federico Sackmann and Fuentes, {Ana Kerguelen} and Dolores Hern{\'a}ndez-Maraver and Pahl, {Heike L.} and Martin Griesshammer and Frank Stegelmann and Konstanze D{\"o}hner and Thomas Lehmann and Karin Bonatz and Andreas Reiter and Francoise Boyer and Gabriel Etienne and Ianotto, {Jean Christophe} and Dana Ranta and Lydia Roy and Cahn, {Jean Yves} and Harrison, {Claire N.} and Deepti Radia and Pablo Muxi and Norman Maldonado and Carlos Besses and Francisco Cervantes and Johansson, {Peter L.} and Tiziano Barbui and Giovanni Barosi and Vannucchi, {Alessandro M.} and Chiara Paoli and Francesco Passamonti and Bjorn Andreasson and Ferrari, {Maria L.} and Alessandro Rambaldi and Jan Samuelsson and Keith Cannon and Gunnar Birgegard and Zhijian Xiao and Zefeng Xu and Yue Zhang and Xiujuan Sun and Junqing Xu and Kiladjian, {Jean Jacques} and Peihong Zhang and Gale, {Robert Peter} and Mesa, {Ruben A.}",
year = "2017",
doi = "10.3324/haematol.2016.149559",
language = "English (US)",
volume = "102",
pages = "85--93",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "1",

}

TY - JOUR

T1 - Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms

T2 - An analysis by the MPN QOL international working group

AU - Geyer, Holly L.

AU - Kosiorek, Heidi

AU - Dueck, Amylou

AU - Scherber, Robyn

AU - Slot, Stefanie

AU - Zweegman, Sonja

AU - te Boekhorst, Peter A W

AU - Senyak, Zhenya

AU - Schouten, Harry C.

AU - Sackmann, Federico

AU - Fuentes, Ana Kerguelen

AU - Hernández-Maraver, Dolores

AU - Pahl, Heike L.

AU - Griesshammer, Martin

AU - Stegelmann, Frank

AU - Döhner, Konstanze

AU - Lehmann, Thomas

AU - Bonatz, Karin

AU - Reiter, Andreas

AU - Boyer, Francoise

AU - Etienne, Gabriel

AU - Ianotto, Jean Christophe

AU - Ranta, Dana

AU - Roy, Lydia

AU - Cahn, Jean Yves

AU - Harrison, Claire N.

AU - Radia, Deepti

AU - Muxi, Pablo

AU - Maldonado, Norman

AU - Besses, Carlos

AU - Cervantes, Francisco

AU - Johansson, Peter L.

AU - Barbui, Tiziano

AU - Barosi, Giovanni

AU - Vannucchi, Alessandro M.

AU - Paoli, Chiara

AU - Passamonti, Francesco

AU - Andreasson, Bjorn

AU - Ferrari, Maria L.

AU - Rambaldi, Alessandro

AU - Samuelsson, Jan

AU - Cannon, Keith

AU - Birgegard, Gunnar

AU - Xiao, Zhijian

AU - Xu, Zefeng

AU - Zhang, Yue

AU - Sun, Xiujuan

AU - Xu, Junqing

AU - Kiladjian, Jean Jacques

AU - Zhang, Peihong

AU - Gale, Robert Peter

AU - Mesa, Ruben A.

PY - 2017

Y1 - 2017

N2 - The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life. The role gender plays in the symptomatology of myeloproliferative neoplasms remains underinvestigated. In this study we evaluated how gender relates to patients’ characteristics, disease complications and overall symptom expression. A total of 2,006 patients (polycythemia vera=711, essential thrombocythemia= 830, myelofibrosis=460, unknown=5) were prospectively evaluated, with patients completing the Myeloproliferative Neoplasm-Symptom Assessment Form and Brief Fatigue Inventory Patient Reported Outcome tools. Information on the individual patients’ characteristics, disease complications and laboratory data was collected. Consistent with known literature, most female patients were more likely to have essential thrombocythemia (48.6% versus 33.0%; P<0.001) and most male patients were more likely to have polycythemia vera (41.8% versus 30.3%; P<0.001). The rate of thrombocytopenia was higher among males than females (13.9% versus 8.2%; P<0.001) and males also had greater redblood cell transfusion requirements (7.3% versus 4.9%; P=0.02) with shorter mean disease duration (6.4 versus 7.2 years, P=0.03). Despite there being no statistical differences in risk scores, receipt of most therapies or prior complications (hemorrhage, thrombosis), females had more severe and more frequent symptoms for most individual symptoms, along with overall total symptom score (22.8 versus 20.3; P<0.001). Females had particularly high scores for abdominal-related symptoms (abdominal pain/discomfort) and microvascular symptoms (headache, fatigue, insomnia, concentration difficulties, dizziness; all P<0.01). Despite complaining of more severe symptom burden, females had similar quality of life scores to those of males. The results of this study suggest that gender contributes to the heterogeneity of myeloproliferative neoplasms by influencing phenotypic profiles and symptom expression.

AB - The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life. The role gender plays in the symptomatology of myeloproliferative neoplasms remains underinvestigated. In this study we evaluated how gender relates to patients’ characteristics, disease complications and overall symptom expression. A total of 2,006 patients (polycythemia vera=711, essential thrombocythemia= 830, myelofibrosis=460, unknown=5) were prospectively evaluated, with patients completing the Myeloproliferative Neoplasm-Symptom Assessment Form and Brief Fatigue Inventory Patient Reported Outcome tools. Information on the individual patients’ characteristics, disease complications and laboratory data was collected. Consistent with known literature, most female patients were more likely to have essential thrombocythemia (48.6% versus 33.0%; P<0.001) and most male patients were more likely to have polycythemia vera (41.8% versus 30.3%; P<0.001). The rate of thrombocytopenia was higher among males than females (13.9% versus 8.2%; P<0.001) and males also had greater redblood cell transfusion requirements (7.3% versus 4.9%; P=0.02) with shorter mean disease duration (6.4 versus 7.2 years, P=0.03). Despite there being no statistical differences in risk scores, receipt of most therapies or prior complications (hemorrhage, thrombosis), females had more severe and more frequent symptoms for most individual symptoms, along with overall total symptom score (22.8 versus 20.3; P<0.001). Females had particularly high scores for abdominal-related symptoms (abdominal pain/discomfort) and microvascular symptoms (headache, fatigue, insomnia, concentration difficulties, dizziness; all P<0.01). Despite complaining of more severe symptom burden, females had similar quality of life scores to those of males. The results of this study suggest that gender contributes to the heterogeneity of myeloproliferative neoplasms by influencing phenotypic profiles and symptom expression.

UR - http://www.scopus.com/inward/record.url?scp=85008395907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008395907&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.149559

DO - 10.3324/haematol.2016.149559

M3 - Article

C2 - 27540137

AN - SCOPUS:85008395907

VL - 102

SP - 85

EP - 93

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -